PL
CRNC icon

Pluribus Labs’s Cerence CRNC Stock Holding History

Pluribus Labs’s Portfolio CRNC Stock Details CRNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,031
Closed -$386K – 96
2021
Q4 		$386K Buy
+5,031
New +$444K 0.41% 87

Other funds holding CRNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

Pluribus Labs's CRNC Position: Q1 2022 in Review

Pluribus Labs sold out of Cerence (CRNC) in Q1 2022, closing a stake of 5,031 shares — an estimated $386K sold.

Pluribus Labs first reported a position in CRNC in Q4 2021 and held it in 1 quarter. The position peaked at $386K in Q4 2021. 286 funds tracked by Wall St. Rank hold CRNC as of Q1 2022.

  • Pluribus Labs reported no remaining Cerence position as of Q1 2022 after selling out during the quarter.
  • Pluribus Labs sold 5,031 Cerence shares in Q1 2022, an estimated $386K.
  • Pluribus Labs first reported a position in Cerence in Q4 2021 and held it in 1 quarter.
  • Pluribus Labs's Cerence position peaked at $386K in Q4 2021.
  • 286 funds tracked by Wall St. Rank held Cerence as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.